Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis

Free Radical Biology and Medicine

Volumn 52, Issue 9, 2012, Pages 1987-1999

  Noori, Shokoofe ^a   Hassan, Zuhair M ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Akt; Apoptosis; CDK4; Cell cycle arrest; Free radicals; p27kip1 cyclinD1; PI3K; Tehranolide

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOCHROME C; FAS ANTIGEN; LIPOCORTIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SESQUITERPENE LACTONE DERIVATIVE; TEHRANOLIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; G0 PHASE; G1 PHASE; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; SESQUITERPENES;

EID: 84859491411     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.01.026     Document Type: Article

References (62)

1. M. Krapcho, M.J.R.L. Horner, N. Neyman, R. Aminou, N. Howlader, E.J. Feuer, S.F. Altekruse, L. Huang, A. Mariotto, D.R. Lewis, B.A. Miller, M.P. Eisner, B.K. Edwards, and D.G. Stinchcomb SEER Cancer Statistics Review 2008 Natl. Cancer Inst., Natl. Inst. of Health Bethesda
2. American Cancer Society Breast Cancer Facts & Figures 2007-2008 2007 American Cancer Society Atlanta, Georgia www.cancer.org/downloads/STT/BCFF- Final.pdf. (Accessed in June 2009)
3. D.J. Newman, G.M. Cragg, and K.M. Snader Natural products as sources of new drugs over the period 1981-2002 J. Nat. Prod. 66 2003 1022 1037
4. D.L. Klayman Qinghaosu (artemisinin): an antimalarial drug from China Science 228 1985 1049 1055
5. S.R. Meshnick, T.E. Taylor, and S. Kamchonwongpaisan Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy Microbiol. Mol. Biol. Rev. 60 1996 301
6. A. Yeka, K. Banek, N. Bakyaita, S.G. Staedke, M.R. Kamya, and A. Talisuna Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda PLoS Med. 2 2005 654
7. V.B. Konkimalla, M. Blunder, E. Thedinga, B. Korn, R. Bauer, and T. Efferth Artemisinin derivatives induce generation of nitric oxide and reactive oxygen species in cell lines of hematopoietic origin Nitric Oxide 17 2007 21 22 [Poster abstracts]
8. Z.M. Qian, H. Li, H. Sun, and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 54 2002 561 587
9. P.T. Gomme, K.B. McCann, and J. Bertolini Transferrin: structure, function and potential therapeutic actions Drug Discov. Today 10 2005 267 273
10. H. Lai, and N.P. Singh Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a] anthracene (DMBA)-induced breast cancer in the rat Cancer Lett. 231 2006 43 48
11. Y.-Y. Lu, T.-S. Chen, J.-L. Qu, W.-L. Pan, L. Sun, and X.-B. Wei Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells J. Biomed. Sci. 16 2009 16
12. I. Nakase, B. Gallis, T. Takatani-Nakase, S. Oh, E. Lacoste, and N.P. Singh Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis Cancer Lett. 274 2009 290 298
13. I. Nakase, H. Lai, N.P. Singh, and T. Sasaki Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation Int. J. Pharm. 354 2008 28 33
14. S. Oh, B.J. Kim, N.P. Singh, H. Lai, and T. Sasaki Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide Cancer Lett. 274 2009 33 39
15. S. Noori, M. Taghikhani, Z. Hassan, and A. Al-lameh Tehranolide could shift the immune response towards Th1 and modulate the intra-tumor infiltrated T regulatory cells Iran. J. Immunol. 6 2009 216 224
16. S. Noori, M. Taghikhani, Z.M. Hassan, A. Allameha, and A. Mostafaei Tehranolide molecule modulates the immune response, reduces regulatory T cell and inhibits tumor growth in vivo Mol. Immunol. 47 2010 1579 1584
17. I. Sanchez, and B.D. Dynlacht New insights into cyclins, CDKs, and cell cycle control Semin. Cell Dev. Biol. 16 2005 311 321
18. C.J. Sherr, and J.M. Roberts Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev. 9 1995 1149 1163
19. M.A. Shah, and G.K. Schwartz Cyclin-dependent kinases as targets for cancer therapy Cancer Chemother. Biol. Response Modif. 22 2005 135 162
20. D.E. Fisher Apoptosis in cancer therapy: crossing the threshold Cell 78 1994 539 542
21. A.M. Chinnaiyan, C.G. Teppert, M.F. Seidin, K. O'Rourke, F.C. Kischkel, S. Hellbrandt, M.E. Peter, and V.M. Dixil FADD/MORT-I is a common mediator of CD95 (APO-I/Fas) and tumor necrosis factor receptor-induced apoptosis J. Biol. Chem. 271 1996 4961 4965
22. F.C. Kischkel, S. Hellbrandt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer, and M.E. Peter Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signaling complex (DISC) with the receptor EMBO J. 14 1995 5579 5588
23. G. Kroemer, N. Zampami, and S.A. Susin Mitochondrial control of apoptosis Immunol. Today 18 1997 44 51
24. R.M. Kluck, E. Bossy-Welzel, D.R. Green, and D.D. Newmeyer The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis Science 275 1997 1132 1136
25. B. Antonsson, and J.C. Martinou The Bcl-2 protein family Exp. Cell Res. 256 2000 50 57
26. S.V. Singh, Y. Zeng, and D. Xiao Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak Mol. Cancer Ther. 4 2005 1747 1754
27. C. Ferlini, G. Raspaglio, and S. Mozzetti Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance Mol. Pharmacol. 64 2003 51 58
28. J. Alexandre, Y. Hu, W. Lu, H. Pelicano, and P. Huang Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species Cancer Res. 67 2007 3512 3517
29. E.L. Bell, and N.S. Chandel Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species Essays Biochem. 43 2007 17 27
30. H.U. Simon, A. Haj-Yehia, and F. Levi-Schaffer Role of reactive oxygen species (ROS) in apoptosis induction Apoptosis 5 2000 415 418
31. P. Bragado, A. Armesilla, A. Silva, and A. Porras Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation Apoptosis 12 2007 1733 1742
32. M. Hall, and G. Peters Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer Adv. Cancer Res. 68 1996 67 108
33. C.J. Sherr, and J.M. Roberts Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev. 9 1995 1149 1163
34. I. Sanchez, and B.D. Dynlacht New insights into cyclins, CDKs, and cell cycle control Semin. Cell Dev. Biol. 16 2005 311 321
35. J.K. Buolamwini Cell cycle molecular targets in novel anticancer drug discovery Curr. Pharm. Des. 6 2000 379 392
36. M. Knockaert, and L. Meijer Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography Biochem. Pharmacol. 64 2002 819 825
37. M. Knockaert Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol. Sci. 23 2002 417 425
38. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
39. K. Hishikawa, B.S. Oemar, F.C. Tanner, T. Nakaki, T.F. Luscher, and T. Fujii Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7 J. Biol. Chem. 274 1999 37461 37466
40. Z.M. Hassan, R. Yaraee, N. Zare, T. Ghazanfari, A.H. Sarraf Nejad, and B. Nazori Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity Int. Immunopharmacol. 3 2003 1483 1489
41. S.M. Dibartolomeis, and J.P. Moné Apoptosis: a four week laboratory investigation for advanced molecular and cellular biology students Cell Biol. Educ. 724 2003 275 295
42. L.R. Brown Laboratory exercise: a laboratory exercise in comparative DNA analysis Biochem. Mol. Biol. Educ. 31 2003 177 179
43. C.B. Thompson Apoptosis in the pathogenesis and treatment of disease Science 267 1995 1456 1462
44. R.A. Kinloch, J.M. Treherne, L.M. Furness, and I. Hajimohamadreza The pharmacology of apoptosis Trends Pharmacol. Sci. 20 1999 35 42
45. V.M. Dirsch, D.S. Antlsperger, H. Hentze, and A.M. Vollmar Ajoene, an experimental anti-leukemic drug: mechanism of cell death Leukemia 16 2002 74 83
46. L. Gamet-Payrastre, P. Li, S. Lumeau, G. Cassar, M.A. Dupont, S. Chevolleau, N. Gasc, J. Tulliez, and F. Terce Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells Cancer Res. 60 2000 1426 1433
47. J. Klucar, and M. Al-Rubeai G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin FEBS Lett. 400 1997 127 130
48. A.D. Kinghorn, N.R. Farnsworth, D.D. Soejarto, G.A. Cordell, J.M. Pezzuto, and G.O. Udeani Novel strategies for the discovery of plant-derived anticancer agents Pure Appl. Chem. 71 1999 1611 1618
49. N.P. Singh, and H. Lai Selective toxicity of dehydroartemisinin and holotransferrin on human breast cancer cells Life Sci. 70 2001 49 56
50. N.P. Singh, and H. Lai Artemisinin induces apoptosis in human cancer cells Anticancer Res. 24 2004 2277 2280
51. L. Langroudi, Z.M. Hassan, M. Ebtekar, M. Mahdavi, N. Pakravan, and S. Noori A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model Int. Immunopharmacol. 10 2010 1055 1061
52. F. Labat-Moleur, C. Guillermet, and P. Lorimier TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement J. Histochem. Cytochem. 46 1998 327 334
53. H. Mehmet Apoptosis: caspase find a new place to hide Nature 403 2002 29 30
54. P. Reizenstein Iron, free radicals and cancer Med. Oncol. Tumor Pharmacother. 8 1991 229 233
55. N. Shterman, B. Kupfer, and C. Moroz Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines Pathobiology 59 1991 19 25
56. M.A. Shah, and G.K. Schwartz Cyclin-dependent kinases as targets for cancer therapy Cancer Chemother. Biol. Response Modif. 22 2005 135 162
57. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev. 2 2002 489 501
58. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
59. A. Bellacosa, D. de Feo, A.K. Godwin, D.W. Bell, J.Q. Cheng, D.A. Altomare, M. Wan, L. Dubeau, G. Scambia, and V. Masciullo Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
60. G. Viglietto, M.L. Motti, P. Buuni, R.M. Melillo, A. D'Alessio, D. Califano, F. Vinci, G. Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, and M. Santoro Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer Nat. Med. 8 2002 1136 1144
61. L. Hengst, and S.I. Reed Translational control of p27/Kip1 accumulation during the cell cycle Science 271 1996 1861 1864
62. K. Polyak, J.Y. Kato, M. Solomon, C.J. Sherr, J. Massague, J.M. Roberts, and A. Koff p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest Genes Dev. 8 1994 9 22